Viewing nowCombinationDucapozire 60/2.5 mg
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Hwanin Pharmaceutical Co., Ltd.

MFDS item code 202300128 · Approved 2023.01.06 · Insurance code 657203990
Treatment of essential hypertension not adequately controlled with fimasartan monotherapy
This medicine is used for patients with essential hypertension where blood pressure is not sufficiently controlled with Pimasartan potassium alone. It helps manage blood pressure appropriately to reduce cardiovascular risk.
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended to take the tablet at the same time each day (e.g., in the morning), if possible. It is recommended that the dose be adjusted with fimasartan before administering this medicine. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 30 milligrams monotherapy. ㆍ 60/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams monotherapy. ㆍ 60/5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams monotherapy or this medicine 60/2.5 milligrams. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. No initial dose adjustment is required for elderly patients aged 70 years or younger. No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 milligrams in this medicine. No dose adjustment is required in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.
This medicine can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients allergic to any of the ingredients in this medicine or who are pregnant or breastfeeding, patients receiving renal dialysis, patients with moderate to severe liver impairment, patients with biliary obstruction, and patients with certain kidney diseases or diabetic nephropathy should not take this medicine. Special caution is required when taking this medicine if you have reduced blood volume, sodium deficiency, impaired kidney function, renal artery stenosis, aortic stenosis or mitral stenosis, severe hypotension, are elderly, or have allergies to specific coloring agents. Side effects such as dizziness, headache, facial swelling, urination disturbances, insomnia, and flushing may occur when taking this medicine, and various adverse reactions such as kidney function deterioration, hypotension, liver function abnormalities, and skin rashes have been reported rarely. Care must be taken during the initial doses or when the dosage is increased as blood pressure may drop too low, especially if there is dehydration or electrolyte imbalance. This medicine can increase serum potassium levels, so patients at risk for hyperkalemia should have their blood tested regularly. Drug interactions can occur when taken with other antihypertensives, diuretics, potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, etc., so consultation with healthcare professionals is necessary. It should be avoided during pregnancy due to the risk to the fetus, and it is also not recommended during breastfeeding as the drug may be transmitted through breast milk. Safety in children and adolescents under 18 years of age has not been established, and it is advisable not to use it. In case of overdose, hypotension, heart problems, shock state may occur; you should visit a medical institution immediately, and appropriate emergency treatment is required. Keep out of the reach of children, and storing in the original container can help maintain quality.
Not everyone experiences these, and they can vary from person to person.
This medicine is sensitive to light, so it should be stored in a container that blocks light. Additionally, it is important to store the medicine at room temperature between 1 degree and 30 degrees Celsius to maintain its efficacy.
Yellow, rounded square film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Hwanin Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.